TYME TECHNOLOGIES INC (TYME) Stock Price, Quote, News and Overview
NASDAQ:TYME - Nasdaq - US90238J1034 - Common Stock - Currency: USD
TYME Quote, Performance and Key Statistics
0.3107
+0.02 (+8.07%)
The current stock price of TYME is 0.3107 USD. In the past month the price decreased by -2.97%. In the past year, price decreased by -69.84%.
TYME Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 18.08 | 328.52B | ||
| AMGN | AMGEN INC | 13.29 | 148.31B | ||
| GILD | GILEAD SCIENCES INC | 13.72 | 132.17B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | N/A | 113.28B | ||
| REGN | REGENERON PHARMACEUTICALS | 13.46 | 64.41B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 37.97B | ||
| ARGX | ARGENX SE - ADR | 98.48 | 35.30B | ||
| ONC | BEIGENE LTD-ADR | 5.81 | 25.15B | ||
| BNTX | BIONTECH SE-ADR | N/A | 23.51B | ||
| NTRA | NATERA INC | N/A | 20.84B | ||
| BIIB | BIOGEN INC | 8.18 | 18.97B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 17.83B |
Related stock screener links
About TYME
Company Profile
Tyme Technologies, Inc. operates as a biotechnology company, which engages in the development and commercialization of cancer therapies. The company is headquartered in Bedminster, New Jersey and currently employs 13 full-time employees. The company went IPO on 2012-05-25. TYME's lead drug product, SM-88, is an oral investigational modified proprietary tyrosine derivative that interrupt the metabolic processes of cancer cells by breaking down the cells key defenses and leading to cell death through oxidative stress and exposure to the body's natural immune system. TYME is focused on evaluating its preclinical pipeline of novel CMBT programs, and TYME-19 as a potential therapeutic for SARS CoV-2 diseases. Its preclinical pipeline programs SM-88i, TYME-18, TYME-T and TYME-19. The firm is also developing SM-88i, an injectable formulation of SM-88 for the treatment of multiple oncology indications and TYME-18 for the treatment of solid tumors. The firm is utilizing its metabolism-based technology and is developing TYME-19 as a potential therapeutic for coronavirus, the virus that causes Covid-19.
Company Info
TYME TECHNOLOGIES INC
1 Pluckemin Way - Suite 103
Bedminster NEW JERSEY 07921 US
CEO: Richard Cunningham
Employees: 13
Phone: 12124612315.0
TYME TECHNOLOGIES INC / TYME FAQ
What is the stock price of TYME TECHNOLOGIES INC today?
The current stock price of TYME is 0.3107 USD. The price increased by 8.07% in the last trading session.
What is the ticker symbol for TYME TECHNOLOGIES INC stock?
The exchange symbol of TYME TECHNOLOGIES INC is TYME and it is listed on the Nasdaq exchange.
On which exchange is TYME stock listed?
TYME stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for TYME TECHNOLOGIES INC stock?
7 analysts have analysed TYME and the average price target is 9.69 USD. This implies a price increase of 3018.76% is expected in the next year compared to the current price of 0.3107. Check the TYME TECHNOLOGIES INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is TYME TECHNOLOGIES INC worth?
TYME TECHNOLOGIES INC (TYME) has a market capitalization of 53.50M USD. This makes TYME a Micro Cap stock.
How many employees does TYME TECHNOLOGIES INC have?
TYME TECHNOLOGIES INC (TYME) currently has 13 employees.
What are the support and resistance levels for TYME TECHNOLOGIES INC (TYME) stock?
TYME TECHNOLOGIES INC (TYME) has a support level at 0.3 and a resistance level at 0.34. Check the full technical report for a detailed analysis of TYME support and resistance levels.
Should I buy TYME TECHNOLOGIES INC (TYME) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of TYME, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of TYME, evaluating the profitability, health, valuation and growth aspects
- TYME TECHNOLOGIES INC (TYME) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- TYME TECHNOLOGIES INC (TYME) Sales and EPS estimates to see what analysts future expectations are.
- TYME TECHNOLOGIES INC (TYME) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- TYME TECHNOLOGIES INC (TYME) Insider and Institutional Ownership to learn about the owners and their transactions.
- TYME TECHNOLOGIES INC (TYME) Stock Chart to make your own analysis
- TYME TECHNOLOGIES INC (TYME) Latest news and press-releases to stay up to date.
Does TYME TECHNOLOGIES INC (TYME) stock pay dividends?
TYME does not pay a dividend.
When does TYME TECHNOLOGIES INC (TYME) report earnings?
TYME TECHNOLOGIES INC (TYME) will report earnings on 2022-11-07.
What is the Price/Earnings (PE) ratio of TYME TECHNOLOGIES INC (TYME)?
TYME TECHNOLOGIES INC (TYME) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.14).
TYME Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to TYME. When comparing the yearly performance of all stocks, TYME is a bad performer in the overall market: 73.6% of all stocks are doing better.
TYME Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to TYME. TYME scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
TYME Financial Highlights
Over the last trailing twelve months TYME reported a non-GAAP Earnings per Share(EPS) of -0.14. The EPS increased by 22.61% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -30.18% | ||
| ROE | N/A | ||
| Debt/Equity | 0 |
TYME Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 83% to TYME. The Buy consensus is the average rating of analysts ratings from 7 analysts.